So far attenuation of pathogens has been mainly obtained by chemical or heat treatment of microbial pathogens. Recently, live attenuated strains have been produced by genetic modification. We have previously demonstrated that in several prokaryotes as well as in yeasts and mammalian cells the heat shock response is controlled by the membrane physical state (MPS). We have also shown that in Salmonella enterica serovar Typhimurium LT2 (Salmonella Typhimurium) overexpression of a ⌬ 12 -desaturase gene alters the MPS, inducing a sharp impairment of transcription of major heat shock genes and failure of the pathogen to grow inside macrophage (M⌽) (A. Porta et al., J. Bacteriol. 192:1988Bacteriol. 192: -1998Bacteriol. 192: , 2010). Here, we show that overexpression of a homologous ⌬ 9 -desaturase sequence in the highly virulent G217B strain of the human fungal pathogen Histoplasma capsulatum causes loss of its ability to survive and persist within murine M⌽ along with the impairment of the heat shock response. When the attenuated strain of H. capsulatum was injected in a mouse model of infection, it did not cause disease. Further, treated mice were protected when challenged with the virulent fungal parental strain. Attenuation of virulence in M⌽ of two evolutionarily distant pathogens was obtained by genetic modification of the MPS, suggesting that this is a new method that may be used to produce attenuation or loss of virulence in both other intracellular prokaryotic and eukaryotic pathogens. This new procedure to generate attenuated forms of pathogens may be used eventually to produce a novel class of vaccines based on the genetic manipulation of a pathogen's membrane fluid state and stress response.So far, a methodology to obtain live attenuated strains has not been generated for fungal pathogens. With respect to parasites, a live attenuated strain of Toxoplasma has been produced. However, this modified strain was used to develop a vaccine that was considered expensive, caused side effects, and had a short shelf life. Furthermore, the authors emphasized that this vaccine might revert to a pathogenic strain and, therefore, was not considered suitable for human use (17). In Leishmania and other parasites, as yet none of the current candidate subunit vaccines has achieved complete protection reproducibly. Attempts to develop an effective vaccine to control leishmaniasis have been shown to be feasible, but no vaccine is in active clinical use (18). The ability to create genetically modified pathogens by eliminating virulence or essential genes is considered a powerful alternative in the development of an effective protective vaccine. The current genetic procedures are based on the use of specific (virulence) genes that may cause attenuation and are species specific. In other words, a given method of attenuation may be effective in a specific organism but not in other pathogens.We have previously shown in several prokaryotic and eukaryotic cells, including pathogens such as Salmonella (34) and in the human pathogenic fu...